Seagen Inc.

The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.

Phase 3 trial results indicate nivolumab+AVD reduces side effects and disease progression risk by 50% in advanced Hodgkin lymphoma, paving way for pediatric access to checkpoint inhibitors.

Nivolumab plus AVD improved PFS and was better tolerated than brentuximab vedotin plus AVD in a phase 3 trial for advanced Hodgkin lymphoma, with 2-year PFS rates of 92% vs 83% and overall survival rates of 99% vs 98%.

Two studies in NEJM highlight SWOG Statistics and Data Management Center's role at Fred Hutch, challenging lymph node removal in bladder cancer and showing promise for nivolumab plus AVD chemotherapy in Hodgkin lymphoma. The SDMC, celebrating 40 years in Seattle, ensures study design rigor and data integrity, contributing to evidence-based care.

Bristol Myers Squibb’s Opdivo, combined with AVD regimen, significantly improves progression-free survival in stage 3 or 4 Hodgkin’s lymphoma patients compared to Pfizer and Seagen’s Adcetris plus AVD, with reduced risk of disease progression or death and fewer immune-related toxicities.

Nivolumab (Opdivo) reduces side effects and disease progression risk by 50% compared to brentuximab vedotin (Adcetris) in advanced Hodgkin lymphoma treatment, according to a phase 3 clinical trial published in The New England Journal of Medicine.

The global oncology precision medicine market was valued at USD 53.2 billion in 2023 and is expected to grow at a 10.4% CAGR from 2024 to 2032, driven by rising cancer incidence and increasing demand for personalized therapies. Key segments include breast cancer, oral administration, small molecules, and kinase inhibitors. North America leads in market share, with the U.S. accounting for USD 19.7 billion in 2023. Prominent companies include AbbVie, AstraZeneca, and Pfizer, with recent strategic acquisitions enhancing their oncology portfolios.